8-KItem 2.02 · Results of OperationsItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements

Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and…

Filed with the SEC on January 12, 2026 · Summarized by InvestorsBot

Moderna filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibits: 99.1 press release (dated Jan 12, 2026) and 104 Cover Page Inline XBRL. Signed by CFO James M. Mock. No financial statements attached to Item 9.01. $MRNA 📄 #8K #SECfiling

Investors: review Exhibit 99.1 (press release) and the Inline XBRL cover page on EDGAR for details — this 8‑K supplies exhibits/XBRL but does not by itself present standalone financial statements. $MRNA 🔎 #Moderna #biotech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Moderna, Inc.

BREAKING: Moderna reaches settlement with Arbutus/Genevant — $950M up front, royalty-free license covering…

8-K · March 5, 2026

Moderna filed a Form 8‑K on Feb 13, 2026 furnishing a press release (Exhibit 99.1).

8-K · February 13, 2026

Moderna ($MRNA) announced Q4 2025 financial results on Feb 13, 2026 for the quarter ended Dec 31, 2025 —…

8-K · February 13, 2026

Moderna ($MRNA) filed an 8‑K (Item 9.01) on Feb 10, 2026 — Exhibit 99.1: press release dated Feb 10, 2026;…

8-K · February 11, 2026

FDA CBER issued a Refusal-to-File for Moderna’s BLA for investigational influenza vaccine mRNA-1010 — will…

8-K · February 11, 2026

Moderna ($MRNA) said on Feb 10, 2026 it received a Refusal-to-File letter from the FDA for its…

8-K · February 11, 2026